Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$41.6 million.

  • Immunome's Free Cash Flow fell 1657.98% to -$41.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$191.8 million, marking a year-over-year decrease of 10719.31%. This contributed to the annual value of -$118.0 million for FY2024, which is 130453.63% down from last year.
  • According to the latest figures from Q3 2025, Immunome's Free Cash Flow is -$41.6 million, which was down 1657.98% from -$50.3 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Free Cash Flow peaked at $24.0 million during Q1 2023, and registered a low of -$56.7 million during Q1 2025.
  • Moreover, its 3-year median value for Free Cash Flow was -$25.7 million (2024), whereas its average is -$25.0 million.
  • Per our database at Business Quant, Immunome's Free Cash Flow crashed by 33695.47% in 2024 and then plummeted by 1657.98% in 2025.
  • Immunome's Free Cash Flow (Quarter) stood at -$17.8 million in 2023, then crashed by 142.51% to -$43.2 million in 2024, then increased by 3.61% to -$41.6 million in 2025.
  • Its Free Cash Flow stands at -$41.6 million for Q3 2025, versus -$50.3 million for Q2 2025 and -$56.7 million for Q1 2025.